Researchers analyzed data from a large clinical trial involving 559 postmenopausal women with lymph node-negative breast cancer. The study looked at how the drug tamoxifen performed over a period of 25 years to see if it could prevent the cancer from returning.
The results showed that patients whose tumors had high levels of progesterone receptors (PR) saw a significant benefit from taking tamoxifen. In these specific cases, the rate of staying cancer-free was much higher for those on the medication compared to those who did not receive endocrine therapy. However, the study did not find a significant difference in outcomes for patients with low or no progesterone receptor levels.
Because this is a secondary analysis of an existing trial, it provides important information about long-term trends but should be viewed as part of a larger clinical picture. The findings suggest that certain markers can help predict how well tamoxifen works over many years. Patients should talk to their doctors to understand how these specific markers might affect their own treatment plans.
